Long-term Study on Progression Markers in Neurodegenerative Diseases Using Clinical Data and AI

What this Trial Is About

Researchers are studying neurodegenerative diseases to find new early markers for diagnosis and prognosis. This prospective, observational, longitudinal study collects data from patients with conditions like Parkinsons Disease, Lewy Body Dementia, Alzheimers Disease, and other movement or cognitive disorders. The goal is to improve early diagnosis and predict disease progression using clinical evaluations and advanced tools including artificial intelligence AI. Participants undergo routine clinical examinations over 1 to 10 years. Data collected includes movement analysis with motion capture and wearable sensors, brain imaging, neuropsychological and electroencephalographic assessments, and blood chemistry tests. The study also explores AI-powered methods such as voice analysis and handwriting analysis using commercial devices, aiming to support remote diagnosis and monitoring. During the study, participants will be followed with regular clinical visits where various tests and assessments are performed. Researchers will monitor changes in motor and cognitive functions, analyze brain and blood markers, and use AI models to predict disease course. The study plans to track participants for up to 10 years to better understand progression and improve treatment strategies.

Neurodegenerative Diseases Progression Markers (MARKERS-NDD)